OncoMatch/Clinical Trials/NCT06454968
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Is NCT06454968 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Orelabrutinib, obinutuzumab, lenalidomide for marginal zone lymphoma.
Treatment: Orelabrutinib, obinutuzumab, lenalidomide — This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage ANN ARBOR NON-CONTINUOUS STAGE II, STAGE III-IV NON-GASTRIC MALT AND NODAL MZL, LUGANO STAGE II2, LUGANO STAGE IIE, LUGANO STAGE IV
Ann Arbor non-continuous Stage II or Stage III-IV non-gastric MALT and nodal MZL; SMZL (Splenic Marginal Zone Lymphoma); Gastric MALT with Lugano Stage II2/IIE/IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06454968 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ANN ARBOR NON-CONTINUOUS STAGE II or STAGE III-IV NON-GASTRIC MALT AND NODAL MZL or LUGANO STAGE II2 or LUGANO STAGE IIE or LUGANO STAGE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages